Endorecherche. Inc.

8 patents currently held · Updated Nov 14, 2026

5 more in force are now held by other companies

Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Recorded under 2 name spellings.

Ending by 2030

Dec 2026

Next term end

When these terms end

5 yrs10 yrs20 yrs

Held patents by the year their term ends

20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.

3 fees due Jan 4 to 28, 2027 · next Jan 4
1 fee due Aug 4, 2027
The maintenance fee for Treatment of male androgen deficiency symptoms or diseases with sex steroid precursor combined with SERM (US 10,548,903) comes due Aug 4, 2027. Unpaid by Feb 4, 2028, it lapses early.
1 fee due Sep 15, 2027
The maintenance fee for 17alpha-substituted steroids as systemic antiandrogens and selective androgen receptor modulators (US 9,284,345) comes due Sep 15, 2027. Unpaid by Mar 15, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

2 terms have ended since Aug 16, 2026

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.

Showing 1 to 8 of 8

Patent	Title	Status	Expires	Confidence
US 7,709,516	Helix 12 directed non-steroidal antiandrogens In force Term ends Dec 17, 2026 · From the USPTO record	In force	Term ends Dec 17, 2026	From the USPTO record
US 9,090,651	Helix 12 directed pharmaceutical products In force Term ends Sep 23, 2028 · From the USPTO record	In force	Term ends Sep 23, 2028	From the USPTO record
US 10,342,805	Treatment of Alzheimer's Disease, Loss of Cognition, Memory Loss and Dementia with Sex Steroid Precursors in Combination with Selective Estrogen Receptor Modulators In force Term ends Jun 1, 2030 · High confidence	In force	Term ends Jun 1, 2030	High confidence
US 9,284,345	17alpha-substituted steroids as systemic antiandrogens and selective androgen receptor modulators In force Term ends Jan 19, 2031 · From the USPTO record	In force	Term ends Jan 19, 2031	From the USPTO record
US 11,576,891	Methods of Treating or Preventing Estrogen-Related Diseases In force Term ends Jun 16, 2031 · High confidence	In force	Term ends Jun 16, 2031	High confidence
US 10,548,903	Treatment of male androgen deficiency symptoms or diseases with sex steroid precursor combined with SERM In force Ends no later than Mar 4, 2035 · From the USPTO record	In force	Ends no later than Mar 4, 2035	From the USPTO record
US 11,690,852	Reduction of the incidence or recurrence of breast cancer in postmenopausal women treated with intravaginal sex steroid precursor In force Term ends Dec 25, 2041 · From the USPTO record	In force	Term ends Dec 25, 2041	From the USPTO record
US 8,168,627	Helix 12 directed non-steroidal antiandrogens In force Term ended Sep 13, 2026 · From the USPTO record	In force	Term ended Sep 13, 2026	From the USPTO record

Also on record, not counted in the 8: 5 patents in force now held by others · 15 lapsed for an unpaid fee · 52 ended at full term. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built

Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Export every term end as CSV · Pro

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

2 abandoned · 16 no status recorded

List them